Dr David Llobet-Navas
Newcastle University Research Fellow
- Email: firstname.lastname@example.org
- Telephone: : +44(0) 191 241 8631
- Personal Website: https://www.researchgate.net/profile/David_Llobet-Navas
- Address: Institute of Genetic Medicine-Newcastle University
The International Centre for Life
Newcastle Upon Tyne
David Llobet-Navàs (Lleida, 1980) obtained his degree in Biology (1999-2003, Universitat Autònoma de Barcelona, Barcelona). After a research internship he realized his PhD studies in the Institute of Biomedical Research in Lleida (IRB-Lleida) (2004-2009). In the laboratory of Xavier Matias-Guiu and Xavier Dolcet he was initiated in the study of molecular alterations involved in the development and progression of endometrial cancer. His work resulted in seven first-author publications in internationally recognized peer-reviewed journals and received, in 2010, a Premi Sant Jordi Award (August Pi i Sunyer Award of Biochemistry and Physiological Sciences) and the Extraordinary Doctorate Award to the best doctoral thesis by the University of Lleida.
During the course of his PhD he joined the laboratory of John C. Reed (The Sanford-Burnham Institute for Medical Research, 2007) and contributed to seminal studies deciphering the role of BCL-2, TRAF3 and TRAF2 in autoimmunity and Chronic Lymphocytic Leukaemia (CLL). To expand his scientific training he joined the laboratory of Jose Silva (Columbia University and The Mount Sinai School of Medicine, 2009-2015) where he studied the role of microRNAs in mammary gland development and cancer and worked in the identification of new tumour suppressors and breast cancer vulnerabilities by using genome-wide loss of function assays through pooled shRNA-miR screenings.
In 2016, thanks to an Independent Researcher Establishment Scheme Award, David has been recruited into the Institute of Genetic Medicine-Newcastle University where he has established his own group. Our work is currently funded by Newcastle University, the JGW-Patterson Foundation, The Academy of Medical Sciences and Fundacio La Marato de TV3.
To study the link between obesity and cancer development.
Recent studies indicate that 35% of the adult population (aged 20 years and older) worldwide is overweight (body mass index (BMI)=25 kg/m2 or greater), including 12% that is classified as obese (BMI >30 kg/m2). Obesity generates a profound economic burden beyond its evident health impact. As per average, treatment of obesity and associated comorbidities ranges from 2 to 7% of total health care costs per country, making the healthcare expenditures for an obese person 25% higher compared to a person of normal weight at any given age.
Obesity is associated with increased risk of certain types of cancers (e.g., breast and endometrial) and epidemiological studies suggest that 3 to 6% of new cancer cases per year and 3 to 9% of cancer deaths are attributable to high BMI. These exceptional estimations underscore the dramatic impact of high BMI in tumorigenesis and provide a realistic cancer preventive strategy by modulating BMI.
Although the mechanistic processes that could explain the intimate relation between obesity and cancer are multiple, preventative strategies are still based on dietary modifications or exercise regimens. By implementing a multidisciplinary approach based on molecular and cellular techniques combined with genome-wide functional assays, computational analysis, mouse models and patient tissue sample analysis, my research group will investigate how specific genes (regular coding and non-coding genes, particularly microRNAs) regulate fat tissue homeostasis and simultaneously impact tumorigenic events to design novel and complementary therapeutic approaches.
- Eritja N, Chen BJ, Rodríguez-Barrueco R, Santacana M, Gatius S, Vidal A, Martí MD, Ponce J, Bergadà L, Yeramian A, Encinas M, Ribera J, Reventós J, Boyd J, Villanueva A, Matias-Guiu X, Dolcet X, Llobet-Navàs D. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 2017, 13(3), 608-624.
- Eritja N, Yeramian A, Chen BJ, Llobet-Navas D, Ortega E, Colas E, Abal M, Dolcet X, Reventos J, Matias-Guiu X. Endometrial Carcinoma: Specific Targeted Pathways. In: Hedrick Ellenson, L, ed. Molecular Genetics of Endometrial Carcinoma. Switzerland: Springer, 2017, pp.149-207.
- Maiques O, Macià A, Moreno S, Barceló C, Santacana M, Vea A, Herreros J, Gatius S, Ortega E, Valls J, Chen BJ, Llobet-Navas D, Matias-Guiu X, Cantí C, Marti RM. Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma. British Journal of Dermatology 2017, [Epub Ahead of Print].
- Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, Finetti P, Llobet-Navas D, Silva JM. miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes & Development 2017, 31, 553-566.
- Zhang J, An X, Han Y, Ma R, Yang K, Zhang L, Chi J, Li W, Llobet-Navas D, Xu Y, Jiang Y. Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma. Cell Death and Disease 2016, 7, e2358.
- Chiu HS, Llobet-Navas D, Yang X, Chung WJ, Ambesi-Impiombato A, Iyer A, Kim HR, Seviour EG, Luo Z, Sehgal V, Moss T, Lu Y, Ram P, Silva J, Mills GB, Califano A, Sumazin P. Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Research 2015, 25, 257-267.
- Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J. HDAC6 activity is a non-oncogene addiction hub for in inflammatory breast cancers. Breast Cancer Research 2015, 17, 149.
- Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, Silva JM. Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers. Genes & Development 2015, 29(15), 1631-1648.
- Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navas D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA. A NOTCH1-driven MYC enhancer promotes T-cell development, transformation and acute lymphoblastic leukemia. Nature Medicine 2014, 20, 1130-1137.
- Sanchez-Garcia F, Villagrasa P, Matsui J, Kotliar D, Castro V, Akavia UD, Chen BJ, Saucedo-Cuevas L, Rodriguez-Barrueco R, Llobet-Navas D, Silva JM, Pe'er D. Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers. Cell 2014, 159(6), 1461-1475.
- Llobet-Navas D, Rodríguez-Barrueco R, Castro V, Ugalde AP, Sumazin P, Jacob-Sendler D, Demircan B, Castillo-Martín M, Putcha P, Marshall N, Villagrasa P, Chan J, Sanchez-Garcia F, Pe'er D, Rabadán R, Iavarone A, Cordón-Cardó C, Califano A, López-Otín C, Ezhkova E, Silva JM. The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes & Development 2014, 28, 765-782.
- Llobet-Navas D, Rodriguez-Barrueco R, de-la-Iglesia-Vicente J, Olivan M, Castro V, Saucedo-Cuevas L, Marshall N, Putcha P, Castillo-Martin M, Bardot E, Ezhkova E, Iavarone A, Cordon-Cardo C, Silva JM. The microRNA-424/503 cluster reduces CDC25A expression during cell cycle arrest imposed by β in mammary epithelial cells. Molecular and Cellular Biology 2014, 34(23), 4216-4231.
- Pérez-Chacón G, Llobet D, Pardo C, Pindado J, Choi Y, Reed JC, Zapata JM. TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice. Journal of Immunology 2012, 189, 1053-61.
- Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J, Califano A. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011, 147, 370-81.
- Llobet D, Eritja N, Domingo M, Bergada L, Mirantes C, Santacana M, Pallares J, Macià A, Yeramian A, Encinas M, Moreno-Bueno G, Palacios J, Lewis RE, Matias-Guiu X, Dolcet X. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. American Journal of Pathology 2011, 178, 1529-43.
- Eritja N, Llobet D, Domingo M, Yeramian A, Matias-Guiu X, Dolcet X. A novel 3D culture system of polarized epithelial cells to study endometrial carcinogenesis. American Journal of Pathology 2010, 176, 2722-31.
- Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. European Journal of Cancer 2010, 46, 836-50.
- Pallarés J, Llobet D, Santacana M, Eritja N, Puente S, López S, Palomar-Asenjo V, Yeramian A, Dolcet X, Matias-Guiu X. CK2β is expressed in endometrial carcinoma, and has a role in apoptosis resistance and cell proliferation. American Journal of Pathology 2009, 174, 287-96.
- Zapata JM, Llobet D, Krajewska M, Lefebvre S, Kress CL, Reed JC. Lymphocyte-specific TRAF3-transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood 2009, 113, 4595-603.
- Llobet D, Pallarés J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X, Matias-Guiu X. Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutical viewpoints. Journal of Clinical Pathology 2009, 62, 777-85.
- Llobet D, Eritja N, Sorolla A, Yeramian A, Schoenenberger JA, Llombart-Cussac A, Martí RM, Matias-Guiu X, Dolcet X. Antioxidants block proteasome inhibitors function in endometrial carcinoma cells. Anticancer Drugs 2008, 19, 115-24.
- Llobet D, Eritja N, Encinas M, Llecha N, Yeramian A, Pallarés J, Sorolla A, González-Tallada FJ, Matias-Guiu X. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 2008, 27, 2513-24.
- Dolcet X, Llobet D, Encinas M, Pallarés J, Cabero A, Schoenenberger JA, Comella JX, Matias-Guiu X. Proteasome inhibitors induce death but activate NF-kappa B on endometrial carcinoma cell lines and primary culture explants. Journal of Biological Chemistry 2006, 281, 22118-30.
- Dolcet X, Llobet D, Pallarés J, Comella JX, Matias-Guiu X. Flip is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Laboratory Investigation 2005, 85, 885-94.
- Dolcet X, Llobet D, Pallarés J, Matias-Guiu X. NF-KappaB in development and progression of cancer. Virchows Archiv 2005, 446, 475-82.